Pemberton C. Prognostic outcomes in patients with heart failure: a New SuPAR biomarker for risk prediction? JACC Heart Fail. 2017;5(4):278–9. https://doi.org/10.1016/j.jchf.2017.02.009.

Article  PubMed  Google Scholar 

Kotta PA, Nambi V, Bozkurt B. Biomarkers for heart failure prediction and prevention. J Cardiovasc Dev Dis. 2023;10(12):488. https://doi.org/10.3390/jcdd10120488.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huet F, Dupuy AM, Duflos C, Reis CA, Kuster N, Aguilhon S, et al. Soluble urokinase-type plasminogen activator receptor strongly predicts global mortality in acute heart failure patients: insight from the STADE-HF registry. Future Sci OA. 2021;7(5):FSO697. https://doi.org/10.2144/fsoa-2020-0197.

Article  CAS  Google Scholar 

Dupuy AM, Kuster N, Bargnoux AS, Aguilhon S, Huet F, Leclercq F, et al. Long term pronostic value of suPAR in chronic heart failure: reclassification of patients with low MAGGIC score. Clin Chem Lab Med. 2021;59(7):1299–306. https://doi.org/10.1515/cclm-2020-0903.

Article  CAS  PubMed  Google Scholar 

Velissaris D, Zareifopoulos N, Koniari I, Karamouzos V, Bousis D, Gerakaris A, et al. Soluble urokinase plasminogen activator receptor as a diagnostic and prognostic biomarker in cardiac disease. J Clin Med Res. 2021;13(3):133–42. https://doi.org/10.14740/jocmr4459.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Koch A, Tacke F. Why high suPAR is not super - diagnostic, prognostic and potential pathogenic properties of a novel biomarker in the ICU. Crit Care. 2011;15(6):1020. https://doi.org/10.1186/cc10577.

Article  PubMed  PubMed Central  Google Scholar 

Roehm B, McAdams M, Hedayati SS. Novel biomarkers of kidney disease in advanced heart failure: beyond GFR and proteinuria. Curr Heart Fail Rep. 2022;19(4):223–35. https://doi.org/10.1007/s11897-022-00557-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morath C, Hayek SS, Döhler B, Nusshag C, Sommerer C, Zeier M, et al. Soluble urokinase receptor and mortality in kidney transplant recipients. Transpl Int. 2022;35:10071. https://doi.org/10.3389/ti.2021.10071.

Article  PubMed  PubMed Central  Google Scholar 

suPARcharging triage [Internet]. suPARnostic® by ViroGates. Available from: https://www.virogates.com/ [Accessed 2023 Mar 28]

Koller L, Stojkovic S, Richter B, Sulzgruber P, Potolidis C, Liebhart F, et al. Soluble urokinase-type plasminogen activator receptor improves risk prediction in patients with chronic heart failure. JACC Heart Fail. 2017;5(4):268–77. https://doi.org/10.1016/j.jchf.2016.12.008.

Article  PubMed  Google Scholar 

Rasmussen LJH, Petersen JEV, Eugen-Olsen J. Soluble urokinase plasminogen activator receptor (suPAR) as a biomarker of systemic chronic inflammation. Front Immunol. 2021;12:780641. https://doi.org/10.3389/fimmu.2021.780641.

Article  CAS  PubMed  PubMed Central  Google Scholar 

BG Medicine US IVD BGM Galectin-3® Kit. [Internet] Available from: https://www.accessdata.fda.gov/cdrh_docs/reviews/K093758.pdf [Accessed 2024 Feb 11]

Presage® ST2 – Heart Failure Prognosis - Sopachem Diagnostics. [Internet] Available from: https://www.sopachem.com/diagnostics/portfolio/presage-st2-assay/ [Accessed 2024 Feb 11]

Lichtenauer M, Jirak P, Wernly B, Paar V, Rohm I, Jung C, et al. A comparative analysis of novel cardiovascular biomarkers in patients with chronic heart failure. Eur J Intern Med. 2017;44:31–8. https://doi.org/10.1016/j.ejim.2017.05.027.

Article  CAS  PubMed  Google Scholar 

Hayek SS, Tahhan AS, Ko YA, Alkhoder A, Zheng S, Bhimani R, et al. Soluble urokinase plasminogen activator receptor levels and outcomes in patients with heart failure. J Card Fail. 2023;29(2):158–67. https://doi.org/10.1016/j.cardfail.2022.08.010.

Article  PubMed  Google Scholar 

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure | European Heart Journal | Oxford Academic. [Internet] Available from: https://academic.oup.com/eurheartj/article/42/36/3599/6358045 [Accessed 2024 Feb 11]

Hayek SS, Sever S, Ko YA, Trachtman H, Awad M, Wadhwani S, et al. Soluble urokinase receptor and chronic kidney disease. N Engl J Med. 2015;373(20):1916–25. https://doi.org/10.1056/NEJMoa1506362.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gruson D, Lepoutre T, Ahn SA, Rousseau MF. Increased soluble ST2 is a stronger predictor of long-term cardiovascular death than natriuretic peptides in heart failure patients with reduced ejection fraction. Int J Cardiol. 2014;172(1):e250-252. https://doi.org/10.1016/j.ijcard.2013.12.101.

Article  PubMed  Google Scholar 

Gruson D, Ferracin B, Ahn SA, Rousseau MF. Comparison of fibroblast growth factor 23, soluble ST2 and Galectin-3 for prognostication of cardiovascular death in heart failure patients. Int J Cardiol. 2015;15(189):185–7. https://doi.org/10.1016/j.ijcard.2015.04.074.

Article  Google Scholar 

Hara A, Niwa M, Kanayama T, Noguchi K, Niwa A, Matsuo M, et al. Galectin-3: a potential prognostic and diagnostic marker for heart disease and detection of early stage pathology. Biomolecules. 2020;10(9):1277. https://doi.org/10.3390/biom10091277.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mirna M, Topf A, Wernly B, Rezar R, Paar V, Jung C, et al. Novel Biomarkers in Patients with Chronic Kidney Disease: An Analysis of Patients Enrolled in the GCKD-Study. J Clin Med. 2020;9(3):886. https://doi.org/10.3390/jcm9030886.

Article  CAS  PubMed  PubMed Central  Google Scholar